Supplemental Information.docx (37.65 kB)
Download file

Supplemental Information: OLIE, ITCC-082: A phase 2 trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.docx

Download (37.65 kB)
posted on 2021-08-12, 10:17 authored by Nathalie Gaspar, Quentin Campbell-Hewson, Jie HuangJie Huang, Chinyere E. Okpara, Francisco Bautista

Supplemental Information - Definitions of study endpoints and relevant details


Eisai Inc.

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.